Medios is one of the leading competency partners and solutions providers for specialty pharmaceuticals in Germany. We cover the most important components of the supply chain in this area. This includes the manufacture and delivery of personalized medicines adhering to the highest quality standards as well as complementary services.
Specialty pharmaceuticals are medicines for patients with rare or chronic diseases, such as cancer, HIV or hepatitis, whose often personalized therapy is lengthy and cost-intensive due to individual requirements.
In order to ensure an optimal pharmaceutical patient care Medios relies on partnership intelligence: the inter-connection of individual actors in the specialty pharmaceutical market as cooperating partners. Long-term cooperation, a solution-oriented approach and the targeted use of high-end technologies are our first priority.
Medios is one of the leading competency partners and solutions providers for specialty pharmaceuticals in Germany. These are medicines for patients with rare or chronic diseases such as cancer, HIV and hepatitis, whose personalized therapy is often tedious and cost-intensive due to their individual requirements.
With our subsidiaries Medios Pharma, Medios Manufaktur and Medios Digital we connect individual market players to form cooperating partners. Our goal is to provide partners and customers with integrated solutions along the value chain, ensuring optimal patient care.
Medios Pharma is a competence partner for specialty pharmaceuticals in Germany. We interact with market participants who specialize in the care of patients with rare or chronic diseases. With our permission for pharmaceutical wholesale in accordance with §52a AMG, we enable the market and demand-oriented supply of our partners with specialty pharmaceutical drugs. Doing so, we focus on oncology, autoimmunology and infectology. We are a market expert with a comprehensive network and many years of experience in the field of specialty pharma. Together with our partners, we achieve the utmost efficiency in the supply structure through a continuous knowledge exchange.
Medios Manufaktur is a manufacturer of specialty pharmaceutical drugs in Germany. With our in-house production of individually tailored medicines and complementary services for pharmacies we cover the most important sections of the supply chain. We follow the highest international quality standards (GMP) when preparing personalized medication. The focus is on, among other things, infusion solutions for the oncology field.
Medios Digital is the internal system provider of Medios Group. We are developing software and infrastructure solutions and are driving the digitization of the business with specialty pharmaceuticals. Our focus is on logistics processes such as purchasing, warehousing and distribution as well as optimized trading processes with integrated interfaces to our customers.
Millions of people worldwide suffer from rare or chronic diseases such as cancer, HIV or hepatitis. This increases the demand for therapies, which are individually tailored to the patients. However, treatment with personalized medicine is usually lengthy and cost-intensive. This poses major health problems.
Medios AG specializes in solving these challenges in healthcare. Our goal is to link individual players in the specialty pharma market and to pool the know-how of the companies in indicative communities for mutual benefit. This results in a partnership-based intelligence that enables the patient to achieve a highly effective and affordable therapy.
Thanks to our principle of partnership intelligence and all the available information, we can anticipate which developments in the specialty pharmaceutical market will be relevant in the future – and offer solutions that are optimally adapted to the respective situation. We owe this growth to our innovative strategy and clear focus.
Our aim is to put the finishing touch on market-oriented approaches based on the joint interests of the market participants, while leveraging the benefits of a collaborative effort within partnerships.
We envision a future where we serve as a catalyst in combining interests and potential synergies from individual specialty fields across all areas of the marketplace.
We’re not interested in demand patterns of the past. We intend to use our group intelligence, which is greater than the sum of its parts, to anticipate what will be relevant in the future. And we have our exceptional growth to thank for this innovative strategy.